Dossier assessment
Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with active ankylosing spondylitis
- Patients who have responded inadequately or are intolerant to conventional therapy: added benefit not proven
- Patients who have responded inadequately or are intolerant to prior therapy with biological antirheumatic drugs: added benefit not proven
Project details
- Project no.
- A23-61
- Commission
- Commission awarded on 03.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed